The Dual PI3K/mTOR Inhibitor, NVP-BEZ235, Is Efficacious Against Follicular Lymphoma

Leukemia - United Kingdom
doi 10.1038/leu.2010.154
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances Nab-Paclitaxel Antitumor Response in Experimental Gastric Cancer

International Journal of Oncology
Cancer ResearchOncology
2013English

Efficacy of the Dual PI3K and mTOR Inhibitor NVP-BEZ235 in Combination With Imatinib Mesylate Against Chronic Myelogenous Leukemia Cell Lines

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2017English

NVP-BEZ235, a Novel Dual PI3K/mTOR Inhibitor, Enhances the Radiosensitivity of Human Glioma Stem Cells in Vitro

Acta Pharmacologica Sinica
MedicinePharmacology
2013English

Specific Apoptosis Induction by the Dual PI3K/mTor Inhibitor NVP-BEZ235 in HER2 Amplified and PIK3CA Mutant Breast Cancer Cells

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2009English

Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines Under Normoxic and Hypoxic Conditions

Breast Cancer: Basic and Clinical Research
Cancer ResearchOncology
2014English

Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

Clinical Cancer Research
Cancer ResearchOncology
2010English

Antitumor Activity of Selective MEK1/2 Inhibitor AZD6244 in Combination With PI3K/mTOR Inhibitor BEZ235 in Gefitinib-Resistant NSCLC Xenograft Models

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2014English

Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging

Cancer Research
Cancer ResearchOncology
2008English

Progress Against Follicular Lymphoma

Current Opinion in Hematology
Hematology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy